5-Amino-1MQ Dosing Protocol: What Research Shows and What Remains Unknown

There is no established 5-amino-1MQ dosing protocol for humans. Every number circulating online traces back to rodent studies or anecdotal self-experimentation, not to controlled human trials. That means the dose, the timing, and the cycle length all remain experimental, and anyone considering the compound should discuss it with a licensed healthcare professional first.

What 5-Amino-1MQ Actually Does

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase, an enzyme known as NNMT. Blocking NNMT raises intracellular NAD+ and changes how fat cells handle energy, which is why the compound is studied for obesity and metabolic disease.

The molecule is a permanently charged quinolinium cation. That charge matters for dosing, because charged compounds cross cell membranes and the gut lining far less efficiently than neutral molecules do.

• Target: NNMT inhibition, with downstream effects on NAD+ salvage pathways.
• Research interest: fat-mass reduction, insulin sensitivity, and energy expenditure in animal models.
• Human status: 5-amino-1MQ is not FDA-approved for any human use and has no published human pharmacokinetic data.

What Preclinical Studies Actually Used

Published rodent work typically dosed 5-amino-1MQ in the low single-digit milligrams per kilogram range, given daily by injection or mixed into the diet. Those studies ran for weeks, not months, and measured body composition and glucose handling rather than long-term safety.

Study context	Reported dose	Route	Duration	Reported findings
Diet-induced obese mice	~2.5 mg/kg/day	Subcutaneous injection	2–4 weeks	Lower body weight and fat mass; improved glucose tolerance
Obese mouse models	~5 mg/kg/day	Injection or diet admixture	4–6 weeks	Reduced adiposity; shifts in energy expenditure markers
Cultured adipocytes	Micromolar concentrations	In vitro	Hours	Increased NAD+; altered lipolysis signaling

Naive allometric scaling from those mouse doses lands somewhere around 15 to 40 mg per day for a 70 kg adult. That figure is a mathematical conversion, not a clinical recommendation, and it ignores species differences in absorption, metabolism, and tissue distribution.

How Anecdotal Human Protocols Are Built

Because no human trial exists, the schedules circulating in forums and vendor guides are anecdotal reports. Most follow a predictable pattern: a moderate daily dose, one or two administration times, and a short cycle.

A commonly discussed 5-amino-1mq dosage protocol involves 50 to 150 mg per day taken orally, usually split into a morning and an afternoon dose. A smaller group reports subcutaneous injections in the 10 to 50 mg range, hoping to bypass the absorption limits of an oral, charged molecule.

Route	Anecdotal range	Frequency	Practical notes
Oral	50–150 mg/day	Once or twice daily	Convenient; absorption is uncertain
Subcutaneous	10–50 mg/day	Once daily	Used to avoid gut absorption limits; sterility matters
Cycle length	4–8 weeks	Followed by a break	No data supports any specific cycle

Timing claims also vary. Some users take it fasted in the morning, while others take it with food. No study has compared fed versus fasted administration in humans, so those preferences are guesswork rather than evidence.

Comparing 5-Amino-1MQ With Other Research Compounds

People rarely evaluate 5-amino-1MQ in isolation. It is usually compared with other metabolic and mitochondrial research peptides, which is why searches such as slu-pp-332 vs 5-amino-1mq and 5-amino-1mq vs tesamorelin appear so often.

Compound	Mechanism	Common research dose	Human evidence
5-Amino-1MQ	NNMT inhibition	2.5–5 mg/kg/day in mice	None
SLU-PP-332	ERR agonist (exercise mimetic)	~50 mg/kg in mouse studies	None
Tesamorelin	GHRH analog	2 mg/day subcutaneous	FDA-approved for HIV-associated lipodystrophy
AOD-9604	hGH fragment 176-191	300 mcg/day in trials	Mixed, limited results
SS-31 (elamipretide)	Mitochondria-targeted tetrapeptide	40 mg/day subcutaneous in trials	Investigational

The practical takeaway is that tesamorelin has regulatory approval and human dosing data, while 5-amino-1MQ, SLU-PP-332, AOD-9604, and SS-31 have no approved human dose for fat loss. When people compare options, the aod 9604 dosing protocol and the ss-31 peptide dosing protocol at least rest on human trial data, even where the results were modest.

Stacking is another frequent topic. Threads about SLU-PP-332 taken alongside 5-amino-1MQ usually debate whether overlapping metabolic pathways create additive effects or simply add unknown risk. No study has tested that combination in animals or humans.

Safety, Sourcing, and Legal Status

5-amino-1MQ is sold as a research chemical labeled for laboratory use only, not as a dietary supplement or an approved drug. That labeling exists because the safety data required for human use does not exist.

• Known risks: With no human safety dataset, both common side effects and rare serious events are unknown.
• Theoretical concerns: NNMT is expressed in many tissues, so long-term enzyme inhibition could affect more than fat cells.
• Quality issues: Research-grade powders vary widely in purity, and injectable use adds sterility and endotoxin risk.
• Legal status: 5-amino-1MQ is not a controlled substance in the United States, but importing unapproved substances for personal use can create customs and legal problems.

Anyone who proceeds anyway should at minimum use third-party tested material with a certificate of analysis and avoid combining compounds without medical supervision.

What to Ask a Healthcare Professional

Bring the question to a clinician who knows your history instead of relying on vendor guidance. Useful baseline labs include a complete blood count, comprehensive metabolic panel, lipid panel, HbA1c, fasting insulin, and liver enzymes.

1. Ask whether any of your current medications interact with NAD+-modulating compounds.
2. Ask how often to repeat labs if you start an experimental protocol.
3. Ask which symptoms should trigger stopping immediately, such as chest pain, severe fatigue, or unexplained bruising.

The honest summary: 5-amino-1MQ is interesting science with a very thin human evidence base. A dosing protocol built on mouse data and forum posts carries real uncertainty, and no research chemical replaces medical care for weight or metabolic problems.

COMMON QUESTIONS

Frequently Asked Questions

What 5-amino-1MQ dosage protocol do people report using?

Anecdotal reports most often describe 50 to 150 mg per day taken orally, split into one or two doses, with a smaller group reporting 10 to 50 mg per day by subcutaneous injection. These numbers come from self-experimentation, not from controlled human trials. No validated human dose exists.

Is 5-amino-1MQ FDA-approved for human use?

No. 5-amino-1MQ is not FDA-approved for any human indication and is typically sold as a research chemical labeled for laboratory use only. It is also not classified as a dietary supplement, so products are not held to supplement manufacturing standards.

How long do people cycle 5-amino-1MQ?

Most anecdotal protocols run 4 to 8 weeks followed by a break of similar length. That structure is a convention borrowed from other research peptides and is not supported by any human or animal cycling study. Long-term effects of repeated cycles are completely unknown.